Eribulin for advanced HER2-negative breast cancer after ADC therapy
Part of Cancer clinical trials.
This trial tests a chemotherapy drug called eribulin, alone or with other medicines, in people with advanced HER2-negative breast cancer that has already been treated with an antibody-drug conjugate (ADC). It aims to see if eribulin can help when standard ADC treatment has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced breast cancer that cannot be removed by surgery or has spread to other parts of the body
- Your cancer is HER2-negative (a lab test result showing no or low levels of the HER2 protein)
- You have already received an antibody-drug conjugate (ADC) treatment for your advanced cancer
- You have had 2 or fewer types of chemotherapy (including the ADC) for your advanced cancer
- You are willing and able to give informed consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—eribulin (a chemotherapy) and sintilimab (an immunotherapy that helps your immune system attack cancer)—as a first treatment for women with advanced HER2-negative breast cancer that cannot be removed by surgery.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
This trial tests a combination of two drugs, eribulin and bevacizumab, for people with advanced HER2-negative breast cancer. It aims to see how well the treatment works and why it may or may not work.
This trial compares a new every-two-week dosing schedule of the chemotherapy drug eribulin to the standard schedule in people with HER2-negative breast cancer that has returned or spread. The goal is to see if the biweekly regimen is safer or works better.
This trial tests whether adding trastuzumab to eribulin improves outcomes for people with HER2-positive breast cancer that has come back or spread. It’s meant for patients whose cancer has progressed after prior HER2 and chemotherapy treatments.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve outcomes in people with advanced triple-negative breast cancer who have already tried at least two other chemotherapies.
Hear when a new Treatment Efficacy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.